MA41817A - NEW ASSOCIATION BETWEEN 8-CYCLOPROPYL-3- [2- (3-FLUOROPHENYL) ETHYL] -7,8-DIHYDRO-3H- [1,3] OXAZINO [6,5-g] [1,2,3] BENZOTRIAZINE -4,9-DIONE AND AN ANTIDEPRESSANT AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - Google Patents

NEW ASSOCIATION BETWEEN 8-CYCLOPROPYL-3- [2- (3-FLUOROPHENYL) ETHYL] -7,8-DIHYDRO-3H- [1,3] OXAZINO [6,5-g] [1,2,3] BENZOTRIAZINE -4,9-DIONE AND AN ANTIDEPRESSANT AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT

Info

Publication number
MA41817A
MA41817A MA041817A MA41817A MA41817A MA 41817 A MA41817 A MA 41817A MA 041817 A MA041817 A MA 041817A MA 41817 A MA41817 A MA 41817A MA 41817 A MA41817 A MA 41817A
Authority
MA
Morocco
Prior art keywords
oxazino
benzotriazine
antidepressant
dione
fluorophenyl
Prior art date
Application number
MA041817A
Other languages
French (fr)
Inventor
Sylvie Bretin
Laurence Danober
Pierre Lestage
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MA41817A publication Critical patent/MA41817A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
MA041817A 2015-03-26 2016-03-24 NEW ASSOCIATION BETWEEN 8-CYCLOPROPYL-3- [2- (3-FLUOROPHENYL) ETHYL] -7,8-DIHYDRO-3H- [1,3] OXAZINO [6,5-g] [1,2,3] BENZOTRIAZINE -4,9-DIONE AND AN ANTIDEPRESSANT AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT MA41817A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1552563A FR3034019B1 (en) 2015-03-26 2015-03-26 NOVEL ASSOCIATION BETWEEN 8-CYCLOPROPYL-3- [2- (3-FLUOROPHENYL) ETHYL] -7,8-DIHYDRO-3H- [1,3] OXAZINO [6,5-G] [1,2,3] BENZOTRIAZINE -4,9-DIONE AND AN ANTIDEPRESSANT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT

Publications (1)

Publication Number Publication Date
MA41817A true MA41817A (en) 2018-01-30

Family

ID=53776719

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041817A MA41817A (en) 2015-03-26 2016-03-24 NEW ASSOCIATION BETWEEN 8-CYCLOPROPYL-3- [2- (3-FLUOROPHENYL) ETHYL] -7,8-DIHYDRO-3H- [1,3] OXAZINO [6,5-g] [1,2,3] BENZOTRIAZINE -4,9-DIONE AND AN ANTIDEPRESSANT AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT

Country Status (12)

Country Link
EP (1) EP3273996A1 (en)
JP (1) JP2018509436A (en)
KR (1) KR20170125835A (en)
AU (1) AU2016238625A1 (en)
CA (1) CA2975571A1 (en)
FR (1) FR3034019B1 (en)
MA (1) MA41817A (en)
PH (1) PH12017501248A1 (en)
SG (1) SG11201706076QA (en)
TN (1) TN2017000280A1 (en)
WO (1) WO2016151265A1 (en)
ZA (1) ZA201705052B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG163545A1 (en) * 2007-01-03 2010-08-30 Servier Lab 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Also Published As

Publication number Publication date
FR3034019B1 (en) 2017-03-17
CA2975571A1 (en) 2016-09-29
FR3034019A1 (en) 2016-09-30
EP3273996A1 (en) 2018-01-31
TN2017000280A1 (en) 2019-01-16
SG11201706076QA (en) 2017-08-30
ZA201705052B (en) 2019-02-27
PH12017501248A1 (en) 2017-10-30
AU2016238625A1 (en) 2017-08-03
KR20170125835A (en) 2017-11-15
WO2016151265A1 (en) 2016-09-29
JP2018509436A (en) 2018-04-05

Similar Documents

Publication Publication Date Title
SI3453707T1 (en) Benzazepine derivative, preparation method, pharmaceutical composition and use thereof
IL262495B (en) Isoquinoline-3-carboxamide derivatives and pharmaceutical compositions comprising them
ZA201900470B (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
HK1255566A1 (en) Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof
GB201913962D0 (en) Ophthalmic drug compositions
IL254098A0 (en) Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
CL2018000565A1 (en) Compounds derived from pyridinone dicarboxamide, bromodomain inhibitors; pharmaceutical composition; pharmaceutical combination; Useful in the treatment of autoimmune, inflammatory, viral and cancer diseases, among others.
GB201807968D0 (en) Eutectic extract formation and purification
IL272638A (en) Quinoxaline derivatives, their preparation and pharmaceutical compositions containing them
MA54716A (en) REDUCTION OF THE VISCOSITY OF PHARMACEUTICAL FORMULATIONS
IL272446A (en) Substituted penta- fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof
MX2019002057A (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate.
PL3452075T3 (en) Ophthalmic pharmaceutical composition
GB201815035D0 (en) Ophthalmic drug compositions
PT3606511T (en) Pharmaceutical composition comprising lenvatinib mesylate
IL258977B (en) Pyperidyl derivatives, their preparation and pharmaceutical compositions containing them
IL283450A (en) Capsule formulations
ZA201908006B (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
PL3313370T3 (en) Ophthalmologic pharmaceutical composition
IL266859A (en) Solid oral composition containing dyes
PL3176164T3 (en) Optical isomer of 1,4-benzothiazepine-1-oxide derivative, and pharmaceutical composition prepared using same
EP3441075A4 (en) Orally administered essential oil composition and use thereof
MA41817A (en) NEW ASSOCIATION BETWEEN 8-CYCLOPROPYL-3- [2- (3-FLUOROPHENYL) ETHYL] -7,8-DIHYDRO-3H- [1,3] OXAZINO [6,5-g] [1,2,3] BENZOTRIAZINE -4,9-DIONE AND AN ANTIDEPRESSANT AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
FR3019464B1 (en) NOVEL ASSOCIATION BETWEEN 8-CYCLOPROPYL-3- [2- (3-FLUOROPHENYL) ETHYL] -7,8-DIHYDRO-3H- [1,3] OXAZINO [6,5-G] [1,2,3] BENZOTRIAZINE -4,9-DIONE AND AN ACETYLCHOLINESTERASE INHIBITOR AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
GB201520226D0 (en) Pharmaceutical compositions comprising of hetero-bicyclic derivatives, and methodsof use thereof.